Pablo J. Cagnoni
2021
In 2021, Pablo J. Cagnoni earned a total compensation of $5M as President and Chief Executive Officer at Rubius Therapeutics, a 45% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $363,000 |
|---|---|
| Option Awards | $2,996,738 |
| Salary | $597,528 |
| Stock Awards | $1,017,450 |
| Other | $10,918 |
| Total | $4,985,634 |
Cagnoni received $3M in option awards, accounting for 60% of the total pay in 2021.
Cagnoni also received $363K in non-equity incentive plan, $597.5K in salary, $1M in stock awards and $10.9K in other compensation.
Rankings
In 2021, Pablo J. Cagnoni's compensation ranked 2,630th out of 12,415 executives tracked by ExecPay. In other words, Cagnoni earned more than 78.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,630 out of 12,415 | 79th |
Division Manufacturing | 1,038 out of 5,501 | 81st |
Major group Chemicals And Allied Products | 403 out of 2,371 | 83rd |
Industry group Drugs | 353 out of 2,092 | 83rd |
Industry Biological Products, Except Diagnostic Substances | 108 out of 449 | 76th |
Source: SEC filing on March 30, 2022.
Cagnoni's colleagues
We found four more compensation records of executives who worked with Pablo J. Cagnoni at Rubius Therapeutics in 2021.